Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

EdgeRx vs MadeMed

Two GLP-1 desks, one scoreboard. We put EdgeRx and MadeMed head-to-head on the published Brief Score — the same six factors, scored the same way.

No. 33 · Grade B

EdgeRx

Visit EdgeRx Full brief →
vs
Higher Brief ScoreNo. 8 · Grade B

MadeMed

Visit MadeMed Full brief →

The verdict

MadeMed takes this head-to-head.

MadeMed scores 86 to 84 on our six-factor Brief Score — Publishes a price for every dose of every route — which makes it easy to brief, and expensive if you stay low.

That doesn't make EdgeRx a bad call — it's best for men who want a straightforward, disclosed weekly-injectable price on either molecule and value knowing the pharmacy filling the script by name. Weigh the six factors below against your own priorities before you decide.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
84
92
Supply Reliability
84
84
Transparency
82
94
Access Breadth
84
76
Clinical Oversight
88
84
Track Record
80
82
EdgeRxBrief Score 84 · 86MadeMed

Price, coverage & the tracker

EdgeRxMadeMed
Brief Score84/100 (B)86/100 (B)
Semaglutide$229/mo injectable$239/mo injectable · $219/mo sublingual (quarterly)
Tirzepatide$299/mo injectable$399/mo injectable · $299/mo sublingual (quarterly)
Coverage46 states (excludes Arkansas, Indiana, Minnesota, South Carolina)40 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyYes
On the trackerNewnew to the tracker, no prior readingStableprice stable

EdgeRx: First reading — flat weekly-injectable pricing on both molecules, named CMA and named 503A pharmacy.

MadeMed: Publishes one price per route that holds at every dose — the cleanest dose-to-price mapping we track.

Not sold on either?

CoreAge Rx tops the whole board at 94/100.

The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.